ANN ARBOR, Mich.,- Rubicon Genomics, Inc., today reported that its NovaPLEX family of sample preparation technologies is increasing the feasibility and utility of molecular diagnostic testing and helping to address the shortage of patient samples that is hampering new drug discovery and the development of personalized medicine. Rubicon is a leader in the development and commercialization of sample-specific pre-analytical processes to improve the performance and capabilities of DNA and RNA platforms for research and clinical testing.
Rubicon's NovaPLEX family of pre-analytical platforms effectively amplify and standardize DNA and RNA, thereby improving the sensitivity, specificity and reproducibility of the resulting analysis regardless of specimen size, type or condition. Archived patient samples are often scarce and in poor condition, while newly collected patient samples can have features that make accurate analysis difficult. Rubicon's technologies are optimized for preparing samples such as plasma and serum, FFPE tissue, fragmented DNA and single cells for analysis using next generation sequencing and microarray and PCR platforms.
PR Newswire